Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs
Prelude Therapeutics shares rose 5.4% to $3.66 in premarket trading Thursday after the company appeared at the Jefferies Global Healthcare Conference. Incyte holds exclusive rights to buy Prelude’s JAK2V617F program for $100 million plus milestones. Prelude began a Phase 1 trial for PRT12396 and plans a 2026 IND filing for PRT13722. Market cap stands near $302 million.